A new web portal (http://www.mmlandscape.ktn-uk.org/) was launched at the recent 12th Annual bioProcessUK Conference held in Cambridge on 25/6 November 2015. The portal developed by the Knowledge Transfer Network (KTN) on behalf of the Medicines Manufacturing Industry Partnership (MMIP) pulls together the innovation landscape, company base and manufacturing sites for the entire medicines sector in the UK.
In case you couldn’t find us, the Clinical BioManufacturing Facility (CBF) has been listed under 'National Capabilities' rather than ‘Academic Capabilities’ or ‘Manufacturing Sites’; unfortunately as a ‘MHRA accredited academic GMP manufacturing site’ we never seem to fit with people's pigeon holes!
As part of the Regulatory Flexibility workshop at the above conference Sarah Moyle, Head of the CBF, presented an overview of the first in man clinical trial products manufactured by the University of Oxford’s GMP facility (firstly from 1995 as the Therapeutic Antibody Centre or TAC, and since 2005 as the CBF). The CBF has always worked closely with the MHRA for advice and support for manufacturing first in man novel product types. The MHRA Innovation office case study on malaria vaccines describes these early interactions. Over the past 10 years we have continued to engage with the MHRA on several of our other projects in order to expedite the manufacture of novel translational medicines, supporting our academic colleagues in achieving early access to clinic. The Innovation Office has proved very beneficial and we would encourage others to use it.